Name | Ritanserin |
Description | Ritanserin (R 55667) is a long-acting, highly potent, relatively selective, orally bioavailable 5-HT2 receptor antagonist with an IC50 of 0.9 nM. |
In vitro | METHODS: AML cell lines Kasumi-1 and KG-1α were treated with Ritanserin (R 55667) (10, 20, 30, 40, 50, 60 μM), and cytotoxicity was determined by CCK-8.
RESULTSRitanserin (R 55667) significantly reduced the proliferation activity of AML cells in a dose-dependent and time-dependent manner. [1]
Ritanserin (R 55667) has low activity against multiple receptors, including histamine-H1 (IC50, 35 nM), dopamine-D2 (IC50, 70 nM), adrenergic-α1 (IC50, 97 nM), and adrenergic-α2 receptors (IC50, 150 nM).[2] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (104.7 mM), Sonication is recommended.
|
Keywords | Inhibitor | 5-hydroxytryptamine Receptor | inhibit | Serotonin Receptor | R-55667 | Ritanserin | 5-HT Receptor | Beta Receptor | Dopamine Receptor | Adrenergic Receptor | R55667 | Histamine Receptor |
Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Meclizine dihydrochloride | Lidocaine | Famotidine | Octopamine hydrochloride | Sodium butanoate | Oxolinic acid | Alginic acid |
Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |